Ma, Zeliang
Men, Yu
Liu, Yunsong
Bao, Yongxing
Liu, Qian
Yang, Xu
Wang, Jianyang
Deng, Lei
Zhai, Yirui
Bi, Nan
Wang, Luhua
Hui, Zhouguang
Funding for this research was provided by:
National key research and development program (2022YFC2705001)
Capital’s Funds for Health Improvement and Research (2022-1-4022)
Beijing Xisike Clinical Oncology Research Foundation (Y-HR2020ZD-0779)
Beijing Hope Run Special Fund of Cancer Foundation of China (ZZ2021A02)
Article History
Received: 16 March 2024
Accepted: 29 April 2024
First Online: 13 May 2024
Declarations
:
: This study was approved by the Institutional Review Board of National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academic of Medical Sciences and Peking Union Medical College (No. 22/292–3494). Patient informed consent was waived in the retrospective cohort but was obtained in the prospective cohort. All clinical investigations were conducted in accordance with the principles of the Declaration of Helsinki.
: Not applicable.
: The authors declare no competing interests.